On the stock market since 2021, it operates in the world of health and science. It has 44 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
An average decline of 32% a year over the last 4 years — the most striking risk in this picture. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Clearly below the class average.
Clearly below the class average.
Clearly below the class average.
There is growth, but not at top-of-the-class tempo.
Clearly below the class average.
Business Quality: Profit power and business quality trail similar companies in the sector.
Valuation: The stock trades at a price that looks expensive next to its earnings; that can cap future returns.
angles, checked one by one.
The 3 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Cost Efficiency: As sales grow, profit fails to keep the same pace.
An investor who bought at the very peak is down 100% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Sales run at $124K a year. A small number, but proof the product has real buyers.
Over the last 12 months, company executives reported 35 buys and 24 sells. Management buying with its own money is usually read as a good sign.
A loss of $14.8M against $124K in annual sales.
This stock swings about 2.3 times as much as the market average. Big rallies — and big drops — can both happen fast.
At the current pace of spending, the cash lasts less than a year. After that, the company needs to find new money.
On our five-subject report card, AIMD sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: AIMD is a high-risk stock — not yet profitable, and its future rides on its product catching on.